Detail of "88069-67-4"

Reference

Evaluation of the effect of bepridil on paroxysmal a trial fibrillation, Relationship between efficacy and the f-f interval in surface ECG recordings

Evaluation of the effect of bepridil on paroxysmal a trial fibrillation, Relationship between efficacy and the f-f interval in surface ECG recordings. Yoshida, Toru; Niwano, Shinichi; Inuo, Kimiatsu; Saito, Junko; Kojima, Jisho; Ikeda-Murakami, Kazuko; Hara, Hideyuki; Izumi, Tohru ( Department of Internal Medicine, Kitasato University School of Medicine, Sagamihara, Japan). Circulation Journal, 67(1), 11-15 (English) 2003 Japanese Circulation Society. CODEN: CJIOBY. ISSN: 1346-9843. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Bepridil, a multi-ion channel blocker, is effective for some types of cardiac arrhythmias, and so its effect on the paroxysmal atrial fibrillation (PAF) was evaluated in the present study, comparing it with class Ic antiarrhythmic drugs. The relationship between efficacy and the f-f interval in the surface ECG recording was also analyzed. Sixty-one symptomatic PAF patients were randomized to a bepridil group (200 mg/day, n=23) or class Ic drug group (flecainide 100-200 mg/day or pilsicainide 75-150 mg/day, n=38). The drug was considered effective for PAF prevention when symptomatic episodes of PAF were decreased to less than 50% during the follow-up period of 2-6 mo. The f-f interval in the surface 12-lead ECG trace was evaluated during a PAF episode. Both bepridil and the class Ic drugs were effectively prevented PAF (15/23 (65.In this article, certain chemicals are used. Some of their cas registry numbers are 88069-67-4 and 64706-54-3 2%) vs 24/38 (63.1%) patients, NS). In the class Ic drug group, the f-f interval was longer in the effective cases (114±48 ms) than in the non-effective cases (68±26 ms, p=0.0002). In contrast, in the bepridil group the f-f interval was shorter in the effective cases (85±26 ms) than in the non-effective ones (152±45 ms, p=0.0005). When comparing the non-effective cases in the 2 groups, the bepridil group showed a significantly longer f-f interval than the class Ic drug group (p=0.0003). As a result of drug administration, the class Ic drugs prolonged the f-f interval from 78 ± 33 ms to 128 ± 46 ms (p=0.0004) whereas bepridil showed no change (109 ± 39 ms vs 135 ± 47 ms). For clin. PAF prevention, the effect of bepridil matched that of class Ic antiarrhythmic drugs. Because bepridil was effective in PAF patients with relatively shorter f-f intervals without prolonging the f-f interval, bepridil is considered to work mainly as a class III antiarrhythmic drug. .

Differentiation of the Electrophysiological Effects on the Atrial Myocardium Between the Pure Na Channel Blocker, Pilsicainide, and Flecainide

Differentiation of the Electrophysiological Effects on the Atrial Myocardium Between the Pure Na Channel Blocker, Pilsicainide, and Flecainide. Kanemoto, Masashi; Shimizu, Akihiko; Yamagata, Toshihiko; Esato, Masahiro; Ueyama, Takeshi; Yoshiga, Yasuhiro; Kakugawa, Hiroyuki; Kametani, Ryousuke; Inoue, Noriko; Sawa, Akira; Matsuzaki, Masunori (Division of Cardiovascular Medicine, Yamaguchi University Graduate School of Medicine, Japan). Cardiovascular Drugs and Therapy, 18(4), 295-303 (English) 2004 Kluwer Academic Publishers. CODEN: CDTHET. ISSN: 0920-3206. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) The purpose of this study was to identify the difference between the pure Na channel blocker, pilsicainide and Ic-antiarrhythmic drug, flecainide, on the atrial electrophysiol. characteristics. Methods: The subjects consisted of 24 patients (48±12 yr-old: P-group) in whom pilsicainide was administered i.v. (1 mg/kg/10 min) and 31 patients (47±15 yr-old: F-group) in whom flecainide was administered i.v. (2 mg/kg/10 min). The atrial effective refractory period (ERP-A), intra-atrial conduction time (CT), max intra-atrial conduction delay (Max CD), repetitive atrial firing zone (RAFZ), fragmented atrial activity zone (FAZ) and intra-atrial conduction delay zone (CDZ) were measured before and after the drugs. Results: Pilsicainide and flecainide significantly prolonged the ERP-A (211±27 ms to 246±39 ms; p < 0.001, 217±25 ms to 244±33 ms; p < 0.001, resp.) and CT (121±33 ms to 149±43 ms; p < 0.001, 122±22 ms to 153±27 ms; p < 0.001, resp. 54143-55-4 and 88069-67-4 are cas registry numbers of chemicals which are used as reagents here.) to the same degree. However, the Max CD was shortened by pilsicainide, but not by flecainide. The RAFZ, FAZ and CDZ decreased in the P-group (21±25 ms to 4±10 ms; p < 0.01, 24±24 ms to 14±18 ms; p < 0.05, 56±29 ms to 43±32 ms, p < 0.05, resp.), but not in the F-group. Conclusions: The effects of atrial conduction delays may differ between pilsicainide and flecainide. Further examn. will be needed to explain this mechanism. .